• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Imaging Technology May Make Radiation Safer for Prostate Cancer Patients

Medically reviewed by Drugs.com.

By Cara Murez HealthDay Reporter

TUESDAY, July 25, 2023 -- A technique that uses imaging technology as a guide can make radiation therapy safer for patients undergoing treatment for prostate cancer, a new research review finds.

The technology enables clinicians to accurately aim the radiation beams at the prostate, while avoiding bladder, urethra and rectal tissue. This, in turn, reduces short-term side effects for patients, according to researchers who analyzed 29 published studies. They reported their findings online July 24 in the journal Cancer.

The technique is called magnetic resonance-guided daily adaptive stereotactic body radiotherapy (MRg-A-SBRT).

Reviewing studies involving more than 2,500 patients in all, the researchers found that MRg-A-SBRT was associated with a 44% reduction in urinary side effects and a 60% reduction in bowel side effects.

“The study is the first to directly evaluate the benefits of MR-guided adaptive prostate radiation in comparison to another more standard and conventional form of radiation, and it provides support for use of this treatment in the management of prostate cancer,” study co-author Dr. Jonathan Leeman said in a journal news release. He's a radiation oncologist with the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston.

Using this method, doctors can adjust a patient’s radiation plan every day in response to anatomical changes. They can also monitor the position of the prostate in real time while the radiation beam is on.

Although it was becoming more popular, it was unclear whether the technique had an impact on clinical outcomes and side effects compared with other ways of delivering radiation.

Whether the short-term benefits will lead to long-term benefits will require longer follow-up, Leeman said.

It’s also not clear which aspect of the technology is responsible for the improved outcomes.

“It could potentially be the capability for imaging-based monitoring during the treatment or it could be related to the adaptive planning component. Further studies will be needed to disentangle this,” Leeman said.

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted July 2023

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.